Perphenazine

Indications

• FDA-approved for the treatment of schizophrenia in adults, with dosing ranges separated for outpatients and hospitalized patients.
• FDA-approved for the control of severe nausea and vomiting in adults at doses well below the antipsychotic range.
• Off-label use in acute bipolar mania as an adjunct to lithium or valproate when a first-generation agent is preferred or better tolerated.
• Off-label treatment of psychotic depression, historically as a fixed combination with amitriptyline that is no longer marketed in the United States.
• Performed comparably to olanzapine, quetiapine, and risperidone on all-cause discontinuation in the CATIE trial, supporting its continued use.
• Not indicated for dementia-related psychosis or for nonpsychotic anxiety and insomnia, where safer alternatives exist.

Mechanism of action

• Dopamine D2 receptor antagonism of intermediate potency, requiring roughly eight to sixteen milligrams daily for antipsychotic D2 occupancy.
• Extrapyramidal liability sits between haloperidol and chlorpromazine because striatal blockade is only partially offset by weak muscarinic effects.
• Moderate histamine H1 and alpha-1 antagonism produce intermediate sedation and orthostatic hypotension relative to other phenothiazines.
• Blockade of D2 receptors in the chemoreceptor trigger zone provides the strong antiemetic effect exploited at subantipsychotic doses.
• Tuberoinfundibular D2 antagonism raises prolactin substantially, a class effect shared with all typical phenothiazines.

Pharmacokinetics

• Oral bioavailability is roughly 20-25 percent because of extensive first-pass metabolism, with peak concentrations at 1 to 3 hours.
• Elimination half-life is about 9 to 12 hours, which supports two or three times daily dosing during active treatment.
• CYP2D6 is the main metabolic pathway with contributions from CYP1A2 and CYP3A4; poor metabolizers reach much higher exposures.
• The 7-hydroxyperphenazine metabolite is pharmacologically active and contributes to both efficacy and extrapyramidal effects.
• Protein binding is high and elimination is essentially hepatic, with only trace unchanged drug appearing in the urine.

Dosing

• Outpatients typically start at 4-8 mg orally three times daily, then reduce to the lowest dose that maintains symptom control.
• Hospitalized patients may receive 8-16 mg two to four times daily; the labeled maximum is 64 mg/day in total.
• Most stabilized adults do well on 8-32 mg/day in divided doses, and exceeding 24 mg daily sharply increases extrapyramidal symptoms.
• For severe nausea and vomiting, use 8-16 mg/day orally in divided doses, with a ceiling of 24 mg/day for that indication.
• No formal renal adjustment; use lower doses and slower titration in hepatic impairment, and avoid the drug in overt liver disease.
• Taper gradually over several weeks when discontinuing to avoid cholinergic rebound and emergent withdrawal dyskinesias.

Adverse effects

• Extrapyramidal symptoms affect roughly 20-30 percent of patients, with akathisia the most common and dose-related manifestation.
• Tardive dyskinesia accumulates with duration of exposure, and in CATIE perphenazine showed rates broadly similar to comparator atypicals.
• Hyperprolactinemia is frequent and symptomatic, producing amenorrhea, galactorrhea, gynecomastia, and sexual dysfunction.
• Sedation, orthostatic hypotension, dry mouth, and constipation are moderate, more than with haloperidol and less than with chlorpromazine.
• Weight gain and metabolic change are modest, one reason perphenazine remains an option for patients with metabolic vulnerability.
• Rare serious events include neuroleptic malignant syndrome, agranulocytosis, cholestatic jaundice, seizures, and QT prolongation.

Monitoring

• Baseline and semiannual AIMS with an interval extrapyramidal exam at each visit, using more frequent screening in older patients.
• Baseline CBC and liver enzymes, with repeat testing prompted by fever, sore throat, jaundice, or unexplained fatigue.
• Blood pressure sitting and standing during titration, since orthostasis is most likely in the first two weeks and after increases.
• Weight, waist, fasting glucose, and lipids at baseline, at 3 months, and annually thereafter, consistent with antipsychotic standards.
• ECG when cardiac disease, electrolyte abnormality, or another QT-prolonging drug is present, and creatine kinase if rigidity develops.

Interactions

• Strong CYP2D6 inhibitors such as paroxetine, fluoxetine, and bupropion raise perphenazine levels several-fold and increase movement effects.
• CYP1A2 and CYP3A4 inducers including carbamazepine, rifampin, and tobacco smoke lower concentrations and may cause relapse.
• Additive sedation with opioids, benzodiazepines, and alcohol; additive anticholinergic load with benztropine and antihistamines.
• Combined QT-prolonging agents warrant ECG monitoring, and antihypertensives compound the alpha-blockade-mediated orthostatic drop.
• Contraindicated in comatose states, severe CNS depression, blood dyscrasias, liver damage, and known phenothiazine hypersensitivity.

Special populations

• Human pregnancy data show no clear teratogenic signal, but late gestational exposure risks neonatal extrapyramidal and withdrawal signs.
• Small amounts enter breast milk; nursing is generally acceptable with monitoring of the infant for sedation and abnormal movements.
• Pediatric safety and efficacy are not established for children under 12, so use in that group is off-label and specialist-directed.
• Older adults require reduced doses because of heightened tardive dyskinesia, orthostasis, and the boxed dementia mortality warning.
• Renal impairment does not require adjustment; hepatic impairment increases exposure and is a labeled caution or contraindication.

Clinical pearls

• CATIE showed perphenazine matched most atypicals on discontinuation at far lower cost and metabolic risk.
• Divide the daily dose; the 9-12 hour half-life makes once-daily oral dosing prone to trough breakthrough.
• Perphenazine 8 mg approximates haloperidol 2 mg and chlorpromazine 100 mg in potency.